Global Orphan Drugs Market (2020-2026)

Market Forecast by Drugs (Revlimid, Rituxan, Opdivo, Keytruda, Imbruvica, Soliris and Other Orphan Drugs) by Drug Type (biologics and non-biologic), by Therapy Class (oncology, blood, endocrine, central nervous systems, cardiovascular and respiratory) and by Regions (North America, Europe, Asia Pacific, Latin America, Middle East and Africa) and Competitive Landscape

Product Code: ETC037262 Publication Date: Nov 2020 Product Type: Report
Publisher: 6Wresearch No. of Pages: 300 No. of Figures: 90 No. of Tables: 30

The global Orphan Drugs market is anticipated to register a strong growth potential in the coming time zone as a result of an increase in chronic and life-threatening human diseases. A rise in the injection of such drugs leads to low spread of the disease and has been proven evident in its cure and as a result, the demand for such drugs is increasing. However, the aligned supply for the same is not sufficient owing to stringent government regulations and is leading to low growth of the market at present. However, with the unveiling of the true benefits of the drug, the global orphan drugs market is expected to witness a proliferation. Moreover, since the proportion of the affected life-threatening disease population is comparatively small, the demand for the same is low. Since the application of orphan drugs is limited for the cure of such diseases for which cure cannot be found so far, the application is becoming and is expected to become more low owing to cure and treatment for such diseases being revealed by the healthcare sector underpinned by the extensive research and development of the healthcare sector in the developed and developing economies across the globe. However, the use of the drugs is extensively needed for the production of medicines used for the cure of rare diseases, especially in the field of oncology, chemical nervous cells and endocrine. This is leading to an increase in the demand for such drugs by the pharmaceutical sector and is expected to be a growth driving factor for the global orphan drugs market in the coming time zone. Also, a drift in the government incentives and increase in the expenditure for the growth and development of inclusion of such drugs for production of best-in-class pharmaceutics is expected to shape the future market landscape of the global orphan drugs market in the forthcoming years. As a result, it is expected to bring in bountiful opportunities for the potential industrialists and the to be investors of the product and the market to seek a fortunate future business growth in the near future.

According to 6Wresearch, the Global Orphan Drugs Market size is anticipated to register growth during 2020-26. The outbreak of the global pandemic COVID-19 has no doubt, been proven evident in affecting the global Orphan Drugs market. Owing to the majority of the hospitals and healthcare centers being converted into covid care centers, there has been low access to the population regarding the hospital visits and as a result, it has led to significant decline in the look over of the rare disease patients. A rise in the focus of the healthcare specialists towards the COVID-19, the rare diseases patients are suffering and as a result, it is leading to a shortfall in the research efforts and supply chain setbacks. Additionally, an increased risk for immune compromised patients is leading to a rise in the mitigation and reduce the impact of the disease spread, the rise in the need for research setbacks is expected to instigate the extensive supply of the same and is thus, leading to a shortfall in the market gaining potential and as a result, is expected to be a growth degrading factor for the global orphan drugs market. however, with the market ramp up, the market is again expected to gain potential in the forthcoming years.

Third-world Countries are expected to contribute towards the growth in the demand for Orphan Drugs.

The third world countries have low access to rare diseases treatment and as a result, they are the largest contributors of the demand for orphan drugs and are expected to drive the significant growth of the global orphan drugs market. Additionally, the pharmaceutical industry, being aware of the same is contributing towards the unprecedented and free of cost research and medicine contribution with free healthcare access and this, is anticipated to be of great importance for the growth and development of the global orphan drugs market in the coming time zone.

For further knowledge and information of the reader, the names of the third-world countries have been discussed below to enhance the knowledge of the industrialists and to be investors of the market to seek market growth potential in the coming time zone:

  • Croatia
  • Estonia
  • Lithuania
  • Kenya
  • Serbia
  • Romania
  • Kazakhstan
  • Bahrain
  • Jordan
  • Kuwait
  • Lebanon
  • Oman
  • Bangladesh
  • Sri Lanka
  • Tunisia

The Global Orphan Drugs market report thoroughly covers the market by Product, Drug Type, Therapy Class, and key regions including the Asia Pacific, Latin America, Middle East, Europe, North America and Africa. The Global Orphan Drugs market outlook report provides an unbiased and detailed analysis of the on-going Global Orphan Drugs market trends, opportunities/high growth areas, and market drivers which would help the stakeholders to devise and align their market strategies according to the current and future market dynamics.

Key Highlights of the Report:

  • Global Orphan Drugs Market Overview
  • Global Orphan Drugs Market Outlook
  • Global Orphan Drugs Market Forecast
  • Historical Data of Global Orphan Drugs Market Revenues & Volume for the Period 2016-2019
  • Global Orphan Drugs Market Size and Global Orphan Drugs Market Forecast of Revenues & Volume, Until 2026
  • Historical Data of Global Orphan Drugs Market Revenues & Volume, by Product, for the Period 2016-2019
  • Market Size & Forecast of Global Orphan Drugs Market Revenues & Volume, by Product, Until 2026
  • Historical Data of Global Orphan Drugs Market Revenues & Volume, by Drug Type, for the Period 2016-2019
  • Market Size & Forecast of Global Orphan Drugs Market Revenues & Volume, by Drug Type, Until 2026
  • Historical Data of Global Orphan Drugs Market Revenues, by Therapy Class, for the Period 2016-2019
  • Market Size & Forecast of Global Orphan Drugs Market Revenues, by Therapy Class, Until 2026
  • Historical Data of Global Orphan Drugs Market Revenues, by Regions, for the Period 2016-2019
  • Market Size & Forecast of Global Orphan Drugs Market Revenues, by Regions, Until 2026
  • Historical Data of Asia Pacific Orphan Drugs Market Revenues, for the Period 2016-2019
  • Market Size & Forecast of Asia Pacific Orphan Drugs Market Revenues, Until 2026
  • Historical Data of Latin America Orphan Drugs Market Revenues, for the Period 2016-2019
  • Market Size & Forecast of Latin America Orphan Drugs Market Revenues, Until 2026
  • Historical Data of Europe Orphan Drugs Market Revenues, for the Period 2016-2019
  • Market Size & Forecast of Europe Orphan Drugs Market Revenues, Until 2026
  • Historical Data of Middle East Orphan Drugs Market Revenues, for the Period 2016-2019
  • Market Size & Forecast of Middle East Orphan Drugs Market Revenues, Until 2026
  • Historical Data of North America Orphan Drugs Market Revenues, for the Period 2016-2019
  • Market Size & Forecast of North America Orphan Drugs Market Revenues, Until 2026
  • Historical Data of Africa Orphan Drugs Market Revenues, for the Period 2016-2019
  • Market Size & Forecast of Africa Orphan Drugs Market Revenues, Until 2026
  • Market Drivers and Restraints
  • Global Orphan Drugs Market Trends and Industry Life Cycle
  • Porter’s Five Force Analysis
  • Market Opportunity Assessment
  • Global Orphan Drugs Market Share, By Players
  • Global Orphan Drugs Market Share, By Regions
  • Global Orphan Drugs Market Overview on Competitive Benchmarking
  • Company Profiles
  • Key Strategic Recommendations

Markets Covered

The Global Orphan Drugs Market report provides a detailed analysis of the following market segments:

  • By Drugs:
    • Revlimid
    • Rituxan
    • Opdivo
    • Keytruda
    • Imbruvica
    • Soliris
    • Other Orphan Drugs

  • By Drug Type:
    • Biologics
    • Non-Biologics

  • By Therapy Class:
    • Oncology
    • Blood
    • Endocrine
    • Central Nervous Systems
    • Cardiovascular
    • Respiratory

  • By Regions:
    • Asia Pacific
    • North America
    • Latin America
    • Europe
    • Middle East
    • Africa

1.  Executive Summary

2.  Introduction

2.1. Report Description

2.2. Key Highlights

2.3. Market Scope & Segmentation

2.4. Research Methodology

2.5. Assumptions

3.  Global Orphan Drugs Market Overview

3.1.  Global Orphan Drugs Market Revenues, 2016-2026F

3.2.  Global Orphan Drugs Market Revenue Share, By Drugs, 2019 & 2026F

3.3.  Global Orphan Drugs Market Revenue Share, By Drug Type, 2019 & 2026F

3.4.  Global Orphan Drugs Market Revenue Share, By Therapy Class, 2019 & 2026F

3.5.  Global Orphan Drugs Market Revenue Share, By Regions, 2019 & 2026F

3.6.  Global Orphan Drugs Market Industry Life Cycle

3.7.  Global Orphan Drugs Market- Porter’s Five Forces

4.  Global Orphan Drugs Market Dynamics

4.1.  Impact Analysis

4.2.  Market Drivers

4.3.  Market Restraints

5.  Global Orphan Drugs Market Trends

6.  Global Orphan Drugs Market Overview, By Drugs

6.1.  Global Orphan Drugs Market Revenues, By Revlimid, 2016-2026F

6.2.  Global Orphan Drugs Market Revenues, By Rituxan, 2016-2026F

6.3.  Global Orphan Drugs Market Revenues, By Keytruda, 2016-2026F

6.4.  Global Orphan Drugs Market Revenues, By Opdivo, 2016-2026F

6.5.  Global Orphan Drugs Market Revenues, By Imbruvica, 2016-2026F

6.6.  Global Orphan Drugs Market Revenues, By Soliris, 2016-2026F

6.7.  Global Orphan Drugs Market Revenues, By Other Orphan Drugs, 2016-2026F

7.  Global Orphan Drugs Market Overview, By Drug Type

7.1.  Global Orphan Drugs Market Revenues, By Biologics, 2016-2026F

7.2.  Global Orphan Drugs Market Revenues, By Non-Bioloigics, 2016-2026F

8.  Global Orphan Drugs Market Overview, By Therapy Class

8.1.  Global Orphan Drugs Market Revenues, By Oncology, 2016-2026F

8.2.  Global Orphan Drugs Market Revenues, By Endocrine, 2016-2026F

8.3.  Global Orphan Drugs Market Revenues, By Central Nervous Systems, 2016-2026F

8.4.  Global Orphan Drugs Market Revenues, By Cardiovascular, 2016-2026F

8.5.  Global Orphan Drugs Market Revenues, By Blood, 2016-2026F

8.6.  Global Orphan Drugs Market Revenues, By Respiratory, 2016-2026F

9.  Asia Pacific Orphan Drugs Market Overview

9.1. Asia Pacific Orphan Drugs Market Revenues, 2016-2026F

9.2. Asia Pacific Orphan Drugs Market Revenue Share, By Drugs, 2019 & 2026F

9.3. Asia Pacific Orphan Drugs Market Revenue Share, By Drug Type, 2019 & 2026F

9.4. Asia Pacific Orphan Drugs Market Revenue Share, By Therapy Class, 2019 & 2026F

9.5. Asia Pacific Orphan Drugs Market Revenue Share, By Countries, 2019 & 2026F

10.  North America Orphan Drugs Market Overview

10.1. North America Orphan Drugs Market Revenues, 2016-2026F

10.2. North America Orphan Drugs Market Revenue Share, By Drugs, 2019 & 2026F

10.3. North America Orphan Drugs Market Revenue Share, By Drug Type, 2019 & 2026F

10.4. North America Orphan Drugs Market Revenue Share, By Therapy Class, 2019 & 2026F

10.5. North America Orphan Drugs Market Revenue Share, By Countries, 2019 & 2026F

11.  Latin America Orphan Drugs Market Overview

11.1. Latin America Orphan Drugs Market Revenues, 2016-2026F

11.2. Latin America Orphan Drugs Market Revenue Share, By Drugs, 2019 & 2026F

11.3. Latin America Orphan Drugs Market Revenue Share, By Drug Type, 2019 & 2026F

11.4. Latin America Orphan Drugs Market Revenue Share, By Therapy Class, 2019 & 2026F

11.5. Latin America Orphan Drugs Market Revenue Share, By Countries, 2019 & 2026F

12.  Europe Orphan Drugs Market Overview

12.1. Europe Orphan Drugs Market Revenues, 2016-2026F

12.2. Europe Orphan Drugs Market Revenue Share, By Drugs, 2019 & 2026F

12.3. Europe Orphan Drugs Market Revenue Share, By Drug Type, 2019 & 2026F

12.4. Europe Orphan Drugs Market Revenue Share, By Therapy Class, 2019 & 2026F

12.5. Europe Orphan Drugs Market Revenue Share, By Countries, 2019 & 2026F

13.  Middle East Orphan Drugs Market Overview

13.1. Middle East Orphan Drugs Market Revenues, 2016-2026F

13.2. Middle East Orphan Drugs Market Revenue Share, By Drugs, 2019 & 2026F

13.3. Middle East Orphan Drugs Market Revenue Share, By Drug Type, 2019 & 2026F

13.4. Middle East Orphan Drugs Market Revenue Share, By Therapy Class, 2019 & 2026F

13.5. Middle East Orphan Drugs Market Revenue Share, By Countries, 2019 & 2026F

14.  Africa Orphan Drugs Market Overview

14.1. Africa Orphan Drugs Market Revenues, 2016-2026F

14.2. Africa Orphan Drugs Market Revenue Share, By Drugs, 2019 & 2026F

14.3. Africa Orphan Drugs Market Revenue Share, By Drug Type, 2019 & 2026F

14.4. Africa Orphan Drugs Market Revenue Share, By Therapy Class, 2019 & 2026F

14.5. Africa Orphan Drugs Market Revenue Share, By Countries, 2019 & 2026F

15. Global Orphan Drugs Market Competitive Landscape

15.1. Global Orphan Drugs Market, By Companies, 2019

15.2. Asia Pacific Orphan Drugs Market, By Companies, 2019

15.3. North America Orphan Drugs Market, By Companies, 2019

15.4. Latin America Orphan Drugs Market, By Companies, 2019

15.5. Europe Orphan Drugs Market, By Companies, 2019

15.7. Middle East Orphan Drugs Market, By Companies, 2019

15.8. Africa Orphan Drugs Market, By Companies, 2019

16.  Company Profiles

17.  Key Strategic Recommendations

Pricing
  • Single User License
    $ 4,200
  • Department License
    $ 4,650
  • Site License
    $ 5,100
  • Global License
    $ 5,500